Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1954 1
1963 2
1964 3
1966 4
1967 2
1968 4
1969 3
1970 7
1971 1
1972 5
1973 14
1974 9
1975 7
1976 4
1977 10
1978 8
1979 5
1980 8
1981 7
1982 12
1983 6
1984 12
1985 9
1986 8
1987 7
1988 9
1989 12
1990 20
1991 14
1992 27
1993 18
1994 28
1995 29
1996 44
1997 50
1998 41
1999 31
2000 31
2001 28
2002 26
2003 28
2004 23
2005 24
2006 34
2007 42
2008 33
2009 24
2010 26
2011 27
2012 34
2013 51
2014 36
2015 66
2016 65
2017 52
2018 63
2019 45
2020 46
2021 71
2022 69
2023 83
2024 77
2025 98
2026 99

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,608 results

Results by year

Filters applied: . Clear all
Page 1
Hypoblast from human pluripotent stem cells regulates epiblast development.
Okubo T, Rivron N, Kabata M, Masaki H, Kishimoto K, Semi K, Nakajima-Koyama M, Kunitomi H, Kaswandy B, Sato H, Nakauchi H, Woltjen K, Saitou M, Sasaki E, Yamamoto T, Takashima Y. Okubo T, et al. Nature. 2024 Feb;626(7998):357-366. doi: 10.1038/s41586-023-06871-2. Epub 2023 Dec 5. Nature. 2024. PMID: 38052228 Free PMC article.
Generation of 3D lacrimal gland organoids from human pluripotent stem cells.
Hayashi R, Okubo T, Kudo Y, Ishikawa Y, Imaizumi T, Suzuki K, Shibata S, Katayama T, Park SJ, Young RD, Quantock AJ, Nishida K. Hayashi R, et al. Among authors: okubo t. Nature. 2022 May;605(7908):126-131. doi: 10.1038/s41586-022-04613-4. Epub 2022 Apr 20. Nature. 2022. PMID: 35444274
Distributed control circuits across a brain-and-cord connectome.
Bates AS, Phelps JS, Kim M, Yang HH, Matsliah A, Ajabi Z, Perlman E, Delgado KM, Osman MAM, Salmon CK, Gager J, Silverman B, Renauld S, Salman F, Patel J, Collie MF, Fan J, Pacheco DA, Zhao Y, Zhang W, Serratosa Capdevila L, Roberts RJV, Munnelly EJ, Griggs N, Langley H, Moya-Llamas B, Zhang Z, Maloney RT, Yu SC, Sterling AR, Sorek M, Kruk K, Serafetinidis N, Dhawan S, Klemm F, Brooks P, Lesser E, Jones JM, Pierce-Lundgren SE, Lee SY, Luo Y, Cook AP, McKim TH, Giakoumas DS, Gorko B, Ellis-Joyce J, Zhang J, Kophs EC, Falt T, Negron-Morales AM, Burke A, Hebditch J, Willie KP, Willie R, Popovych S, Kemnitz N, Ih D, Lee K, Lu R, Halageri A, Bae JA, Jourdan B, Schwartzman G, Demarest DD, Behnke E, Bland D, Kristiansen A, Skelton J, Stocks T, Garner D, Hernandez A, Kumar S; BANC-FlyWire Consortium; Daly KC, Dorkenwald S, Collman F, Suver MP, Fenk LM, Pankratz MJ, Yao Z, Wang F, Huston SJ, Stürner T, Jefferis GSXE, Eichler K, Seeds AM, Hampel S, Agrawal S, Okubo TS, Zandawala M, Macrina T, Adjavon DY, Funke J, Tuthill JC, Azevedo A, Seung HS, de Bivort BL, Murthy M, Drugowitsch J, Wilson RI, Lee WA. Bates AS, et al. Among authors: okubo ts. Nature. 2026 Jun 8. doi: 10.1038/s41586-026-10735-w. Online ahead of print. Nature. 2026. PMID: 42259917
Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide population.
Casadei-Gardini A, Rimini M, Tada T, Suda G, Shimose S, Kudo M, Cheon J, Finkelmeier F, Lim HY, Rimassa L, Presa J, Masi G, Yoo C, Lonardi S, Tovoli F, Kumada T, Sakamoto N, Iwamoto H, Aoki T, Chon HJ, Himmelsbach V, Pressiani T, Montes M, Vivaldi C, Soldà C, Piscaglia F, Hiraoka A, Sho T, Niizeki T, Nishida N, Steup C, Iavarone M, Di Costanzo G, Marra F, Scartozzi M, Tamburini E, Cabibbo G, Foschi FG, Silletta M, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Tada F, Ohama H, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Kosaka H, Naganuma A, Koizumi Y, Nakamura S, Kaibori M, Iijima H, Hiasa Y, Burgio V, Persano M, Della Corte A, Ratti F, De Cobelli F, Aldrighetti L, Cascinu S, Cucchetti A. Casadei-Gardini A, et al. Among authors: okubo t. Eur J Cancer. 2023 Feb;180:9-20. doi: 10.1016/j.ejca.2022.11.017. Epub 2022 Nov 25. Eur J Cancer. 2023. PMID: 36527976 Free article. Clinical Trial.
Denosumab versus zoledronic acid for osteoporosis treatment in patients with primary biliary cholangitis (the DELTA Study): A multicenter, non-inferiority randomized trial.
Arase Y, Okubo T, Arai T, Abe M, Namisaki T, Uojima H, Matsumoto K, Kakisaka K, Setsu T, Mishima Y, Tsuruya K, Hirose S, Deguchi R, Shiraishi K, Atsukawa M, Ikegami T, Honda A, Terai S, Yoshiji H, Komori A, Tanaka A, Kagawa T. Arase Y, et al. Among authors: okubo t. Hepatol Commun. 2025 Oct 7;9(11):e0827. doi: 10.1097/HC9.0000000000000827. eCollection 2025 Nov 1. Hepatol Commun. 2025. PMID: 41056494 Free PMC article. Clinical Trial.
Alpha-Fetoprotein and Des-Gamma-Carboxy Prothrombin-Based Tumor Marker Score for First-Line Immunotherapy Selection in Hepatocellular Carcinoma.
Tanaka K, Tsuji K, Hiraoka A, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Ishikawa T, Tajiri K, Ochi H, Toyoda H, Koshiyama Y, Ogawa C, Nishikawa H, Nishimura T, Hatanaka T, Kakizaki S, Noritake H, Kawata K, Naganuma A, Kosaka H, Matsui K, Matono T, Kuroda H, Yata Y, Tanaka H, Aoki T, Tamai H, Tada F, Ohama H, Kanayama Y, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Yoshida O, Imai M, Nakamura S, Enomoto H, Kaibori M, Kudo M, Hiasa Y, Kumada T; Real-life Practice Experts for HCC (RELPEC) Study Group; HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan). Tanaka K, et al. Among authors: okubo t. Liver Cancer. 2025 Jul 21;15(2):205-221. doi: 10.1159/000547519. eCollection 2026 May. Liver Cancer. 2025. PMID: 41063740 Free PMC article.
Real-World Comparison of First-Line Atezolizumab plus Bevacizumab and Durvalumab plus Tremelimumab for Unresectable Hepatocellular Carcinoma.
Hiraoka A, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Nishimura T, Tsuji K, Ishikawa T, Tajiri K, Tanaka H, Toyoda H, Ogawa C, Hatanaka T, Kakizaki S, Kawata K, Naganuma A, Kosaka H, Matono T, Kuroda H, Yata Y, Nishikawa H, Imai M, Aoki T, Ochi H, Tamai H, Komatsu S, Matsuura T, Ueda Y, Kim SK, Ohama H, Tada F, Nakamura S, Nakamura Y, Yoshida O, Nouso K, Morishita A, Itokawa N, Okubo T, Arai T, Tsutsui A, Nagano T, Fukunishi S, Tanaka K, Koshiyama Y, Kanayama Y, Noritake H, Enomoto H, Matsui K, Kaibori M, Okamura J, Fukumoto T, Hiasa Y, Kudo M, Kumada T; RELPEC Group; HCC 48 Group. Hiraoka A, et al. Among authors: okubo t. Liver Cancer. 2026 Apr 2. doi: 10.1159/000550924. Online ahead of print. Liver Cancer. 2026. PMID: 42232791 Free PMC article.
Effect of Tirzepatide Treatment on Hepatic Biomarkers in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease and Type 2 Diabetes Mellitus.
Arai T, Atsukawa M, Nagao C, Yamada Z, Rokugo T, Suzuki K, Kitamura M, Higashi T, Koyano K, Hasegawa Y, Kawano T, Ono H, Yoshida Y, Okubo T, Hayama K, Nakagawa-Iwashita A, Itokawa N, Kondo C, Nagao M, Iwabu M, Iwakiri K. Arai T, et al. Among authors: okubo t. Hepatol Res. 2025 Oct;55(10):1346-1352. doi: 10.1111/hepr.14241. Epub 2025 Jul 5. Hepatol Res. 2025. PMID: 40616360
1,608 results